🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Julia Wulfkuhle

George Mason University

ORCID: 0000-0002-0657-692X
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 1%percentile
4.9Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies

Cancer Cell(2022)10.1016/j.ccell.2022.05.005
Top 4%
4.9DataRank
Top 4%329 citations

Christina Yau, Julia Wulfkuhle, Lamorna Brown Swigart, Rosa I. Gallagher, Pei Rong Evelyn Lee +28 more

Papers

Driven by 14 papers — median percentile 96. Top paper: “Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies”.

Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies

Cancer Cell(2022)10.1016/j.ccell.2022.05.005
Top 4%
4.9DataRank
Top 4%329 citations

Christina Yau, Julia Wulfkuhle, Lamorna Brown Swigart, Rosa I. Gallagher, Pei Rong Evelyn Lee +28 more

Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer

npj Breast Cancer(2022)10.1038/s41523-022-00493-z
N/A
0.900DataRank · unranked
27 citations

Andres Forero‐Torres, Douglas Yee, Christina Yau, Denise M. Wolf, John Park +44 more

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer

npj Breast Cancer(2021)10.1038/s41523-021-00337-2
N/A
0DataRank · unranked
29 citations

Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar +50 more

IGF1R and Src inhibition induce synergistic cytotoxicity in HNSCC through inhibition of FAK

Scientific Reports(2021)10.1038/s41598-021-90289-1
N/A
0DataRank · unranked
11 citations

Adam Spencer, Sarah Hall, Jeremy J.P. Shaw, Julia Wulfkuhle, Emanuel F. Petricoin +4 more

Validation of a multicellular tumor microenvironment system for modeling patient tumor biology and drug response

Scientific Reports(2021)10.1038/s41598-021-84612-z
N/A
0DataRank · unranked
6 citations

Stephen A. Hoang, Kristopher D. Rawls, Katherine A. Owen, Michael B. Simmers, Robert A. Figler +5 more

High-throughput profiling of histone post-translational modifications and chromatin modifying proteins by reverse phase protein array

Journal of Proteomics(2022)10.1016/j.jprot.2022.104596
N/A
0DataRank · unranked
21 citations

Zhongcheng Shi, Hsin‐Yi Lu, Ji‐Eun Kim, Wen Bu, Jose A. Villalobos +14 more

Establishment and characterization of patient-derived xenograft from leptomeningeal spread of a rare pediatric anaplastic pleomorphic xanthoastrocytoma (PXA) bearing a CDC42SE2-BRAF fusion

Research Square(2022)10.21203/rs.3.rs-2026518/v1
N/A
0DataRank · unranked
0 citations

Reza Saadatzadeh, Erika A. Dobrota, Josue D. Ordaz, Barbara J. Bailey, Pankita H. Pandya +17 more

Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2256
N/A
0DataRank · unranked
20 citations

Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien +44 more

Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial

Cell Reports Medicine(2023)10.1016/j.xcrm.2023.101312
N/A
0DataRank · unranked
18 citations

Julia Wulfkuhle, Denise M. Wolf, Lamorna Brown Swigart, Christina Yau, Nicholas O’Grady +22 more

Antibody dependent cell-mediated cytotoxicity selection pressure induces diverse mechanisms of resistance

Cancer Biology & Therapy(2023)10.1080/15384047.2023.2269637
N/A
0DataRank · unranked
4 citations

Rossin Erbe, Yongwei Zhang, Theresa Guo, Zoe X. Malchiodi, Rachael Maynard +8 more

Establishment and characterization of patient-derived xenograft of a rare pediatric anaplastic pleomorphic xanthoastrocytoma (PXA) bearing a CDC42SE2-BRAF fusion

Scientific Reports(2023)10.1038/s41598-023-36107-2
N/A
0DataRank · unranked
1 citations

M. Reza Saadatzadeh, Erika A. Dobrota, Josue D. Ordaz, Barbara J. Bailey, Pankita H. Pandya +17 more

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

Cancer Cell(2021)10.1016/j.ccell.2021.05.009
N/A
0DataRank · unranked
335 citations

Christina Yau, Denise M. Wolf, Hyo S. Han, Lili Du, Anne M. Wallace +40 more

Targeted Dynamic Phospho-Proteogenomic Analysis of Gastric Cancer Cells Suggests Host Immunity Provides Survival Benefit

Molecular & Cellular Proteomics(2024)10.1016/j.mcpro.2024.100870
N/A
0DataRank · unranked
0 citations

Midori Iida, Takeshi Iwaya, Akiko Yashima‐Abo, Yuka Koizumi, Akari Endo +16 more

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial

Nature Communications(2021)10.1038/s41467-021-26019-y
N/A
0DataRank · unranked
73 citations

Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, L. J. van ‘t Veer, Douglas Yee +46 more